Hypogammaglobulinemia and exacerbated CD8 T-cell-mediated immunopathology in SAP-deficient mice with chronic LCMV infection mimics human XLP disease.
暂无分享,去创建一个
[1] M. Volkert. STUDIES ON IMMUNOLOGICAL TOLERANCE TO LCM VIRUS. 2. TREATMENT OF VIRUS CARRIER MICE BY ADOPTIVE IMMUNIZATION. , 2009, Acta pathologica et microbiologica Scandinavica.
[2] A. Sher,et al. SAP regulates T cell–mediated help for humoral immunity by a mechanism distinct from cytokine regulation , 2006, Journal of Experimental Medicine.
[3] J. Christensen,et al. Perforin-Deficient CD8+ T Cells Mediate Fatal Lymphocytic Choriomeningitis despite Impaired Cytokine Production , 2006, Journal of Virology.
[4] M. McCausland,et al. Ly9 (CD229)-Deficient Mice Exhibit T Cell Defects yet Do Not Share Several Phenotypic Characteristics Associated with SLAM- and SAP-Deficient Mice1 , 2006, The Journal of Immunology.
[5] Gang Chen,et al. Signaling Lymphocyte Activation Molecule-Associated Protein Is a Negative Regulator of the CD8 T Cell Response in Mice1 , 2005, The Journal of Immunology.
[6] R. Clementi,et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. , 2005, Blood.
[7] S. Tangye,et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. , 2005, The Journal of clinical investigation.
[8] W. Leonard,et al. Defective B cell responses in the absence of SH2D1A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] C. Terhorst,et al. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. , 2005, Journal of immunology.
[10] A. Fischer,et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product , 2005, The Journal of experimental medicine.
[11] S. Tangye,et al. Regulation of NKT cell development by SAP, the protein defective in XLP , 2005, Nature Medicine.
[12] S. Tangye,et al. Molecular and cellular pathogenesis of X‐linked lymphoproliferative disease , 2005, Immunological reviews.
[13] E. Wherry,et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] Hao Wang,et al. Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation. , 2004, Immunity.
[15] B. Hill,et al. SAP Regulates TH2 Differentiation and PKC-θ-Mediated Activation of NF-κB1 , 2004 .
[16] M. Hersberger,et al. Deliberate removal of T cell help improves virus-neutralizing antibody production , 2004, Nature Immunology.
[17] U. Sack,et al. Persistent Hypogammaglobulinemia Following Mononucleosis in Boys Is Highly Suggestive of X-Linked Lymphoproliferative Disease—Report of Three Cases , 2004, Journal of Clinical Immunology.
[18] P. Hodgkin,et al. Targeting Plasma Cells in Autoimmune Diseases , 2004, The Journal of experimental medicine.
[19] E. Wherry,et al. Memory CD8 T-Cell Differentiation during Viral Infection , 2004, Journal of Virology.
[20] A. Thrasher,et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. , 2004, Blood.
[21] Aaruni Khanolkar,et al. Maintenance, Loss, and Resurgence of T Cell Responses During Acute, Protracted, and Chronic Viral Infections1 , 2004, The Journal of Immunology.
[22] R. Welsh,et al. Immunological Memory to Viral Infections1 , 2004 .
[23] K. Nichols,et al. Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. , 2004, Blood.
[24] Zhao-Qi Wang,et al. Mice deficient in the X‐linked lymphoproliferative disease gene sap exhibit increased susceptibility to murine gammaherpesvirus‐68 and hypo‐gammaglobulinemia , 2003, Journal of medical virology.
[25] M. Eck,et al. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease , 2003, Nature Reviews Immunology.
[26] S. Latour,et al. The SLAM family of immune-cell receptors. , 2003, Current opinion in immunology.
[27] E. Wherry,et al. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.
[28] S. Latour,et al. Molecular and immunological basis of X‐linked lymphoproliferative disease , 2003, Immunological reviews.
[29] M. Eck,et al. SAP couples Fyn to SLAM immune receptors , 2003, Nature Cell Biology.
[30] P. Schwartzberg,et al. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation , 2003, Nature Cell Biology.
[31] R. Ahmed,et al. SAP is required for generating long-term humoral immunity , 2003, Nature.
[32] A. Zajac,et al. Ablation of CD8 and CD4 T Cell Responses by High Viral Loads1 , 2003, The Journal of Immunology.
[33] J. Rowley,et al. Silencing of B Cell Receptor Signals in Human Naive B Cells , 2002, The Journal of experimental medicine.
[34] V. Kuchroo,et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon γ production , 2002 .
[35] J. C. de la Torre,et al. Identification of the Lymphocytic Choriomeningitis Virus (LCMV) Proteins Required To Rescue LCMV RNA Analogs into LCMV-Like Particles , 2002, Journal of Virology.
[36] K. Gilmour,et al. X‐Linked lymphoproliferative disease: three atypical cases , 2001, Clinical and experimental immunology.
[37] D. Thorley-Lawson,et al. Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.
[38] M. Ruzek,et al. NK cell functions restrain T cell responses during viral infections , 2001, European journal of immunology.
[39] H. Kanegane,et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus--associated illnesses. , 2001, Blood.
[40] L. Notarangelo,et al. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. , 2001, The Journal of experimental medicine.
[41] T. Pawson,et al. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product , 2001, Nature Immunology.
[42] P. Engel,et al. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. , 2001, Blood.
[43] A. Sher,et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] P. Borrow,et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells , 2001, Nature Immunology.
[45] K. Nichols,et al. CD150 Association with Either the SH2-Containing Inositol Phosphatase or the SH2-Containing Protein Tyrosine Phosphatase Is Regulated by the Adaptor Protein SH2D1A1 , 2001, The Journal of Immunology.
[46] G. Klein,et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. , 2000, Blood.
[47] S. Tangye,et al. Cutting Edge: Functional Requirement for SAP in 2B4-Mediated Activation of Human Natural Killer Cells as Revealed by the X-Linked Lymphoproliferative Syndrome1 , 2000, The Journal of Immunology.
[48] L. Notarangelo,et al. X-Linked Lymphoproliferative Disease 2b4 Molecules Displaying Inhibitory Rather than Activating Function Are Responsible for the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected Cells , 2000 .
[49] W. Friedrich,et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). , 1999, Human molecular genetics.
[50] R. Schreiber,et al. Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway , 1999, Nature Medicine.
[51] S. Tangye,et al. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. , 1999, Journal of immunology.
[52] R. Ahmed,et al. A Role for Perforin in Downregulating T-Cell Responses during Chronic Viral Infection , 1999, Journal of Virology.
[53] J. Altman,et al. Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.
[54] E. Snyder,et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[55] M. V. von Herrath,et al. Evidence for an Underlying CD4 Helper and CD8 T-Cell Defect in B-Cell-Deficient Mice: Failure To Clear Persistent Virus Infection after Adoptive Immunotherapy with Virus-Specific Memory Cells from μMT/μMT Mice , 1998, Journal of Virology.
[56] Jack R. Davis,et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene , 1998, Nature Genetics.
[57] D. Allen,et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.
[58] R. Zinkernagel,et al. Aplastic Anemia Rescued by Exhaustion of Cytokine-secreting CD8+ T Cells in Persistent Infection with Lymphocytic Choriomeningitis Virus , 1998, The Journal of experimental medicine.
[59] R M Zinkernagel,et al. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[60] M. Buchmeier,et al. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells , 1997, Journal of virology.
[61] R. Ahmed,et al. CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection , 1996, Journal of virology.
[62] J. Christensen,et al. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. , 1996, Journal of immunology.
[63] Kenneth G. C. Smith,et al. The phenotype and fate of the antibody‐forming cells of the splenic foci , 1996, European journal of immunology.
[64] Jack R. Davis,et al. X-Linked Lymphoproliferative Disease: Twenty-Five Years after the Discovery , 1995, Pediatric Research.
[65] J. Frelinger,et al. Natural killer cell activity in lymphocytic choriomeningitis virus-infected beta 2-microglobulin-deficient mice. , 1995, International immunology.
[66] R. Welsh,et al. NK cell response to viral infections in beta 2-microglobulin-deficient mice. , 1995, Journal of immunology.
[67] R. Ahmed,et al. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.
[68] R. Ueda,et al. Immune function in mice lacking the perforin gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[69] Rolf M. Zinkernagel,et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.
[70] R. Zinkernagel,et al. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[71] Jack R. Davis,et al. The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. , 1991, Pediatric pathology.
[72] M. Pauza,et al. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. , 1991, American journal of medical genetics.
[73] M. Buchmeier,et al. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection , 1991, Journal of virology.
[74] R. Ahmed,et al. Immune therapy of a persistent and disseminated viral infection , 1987, Journal of virology.
[75] R. Ahmed,et al. Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells , 1987, Journal of virology.
[76] M. Oldstone,et al. Cytoimitiunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system , 1986, Nature.
[77] R. Ahmed,et al. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence , 1984, The Journal of experimental medicine.
[78] H. Ochs,et al. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. , 1983, The Journal of clinical investigation.
[79] H. Ochs,et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. , 1982, The American journal of medicine.
[80] G. Vawter,et al. X-LINKED RECESSIVE PROGRESSIVE COMBINED VARIABLE IMMUNODEFICIENCY (DUNCAN'S DISEASE) , 1975, The Lancet.
[81] F. Bricout. [Lymphocytic choriomeningitis virus and chronic disease]. , 1972, La Nouvelle presse medicale.
[82] L. Martínez Peralta,et al. Lymphocytic choriomeningitis virus , 2005, Archives of Virology.
[83] R. Welsh,et al. Immunological memory to viral infections. , 2004, Annual review of immunology.
[84] B. Hill,et al. SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1. , 2004, Immunity.
[85] S. P. Sidorenko,et al. The dual-function CD150 receptor subfamily: the viral attraction , 2003, Nature Immunology.
[86] S. Latour,et al. Negative regulation of immunoreceptor signaling. , 2002, Annual review of immunology.
[87] V. Kuchroo,et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon gamma production. , 2002, Blood.
[88] P. Engel,et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. , 2001, Annual review of immunology.
[89] R. Zinkernagel,et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. , 1996, Annual review of immunology.
[90] T. Albrecht,et al. Persistent Viral Infections , 1996 .
[91] B. Woda,et al. X-linked lymphoproliferative syndrome. , 1989, Immunodeficiency reviews.
[92] M. Oldstone,et al. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. , 1986, Nature.
[93] C. Pfau,et al. STUDIES ON IMMUNOLOGICAL TOLERANCE TO LCM VIRUS. 4. THE QUESTION OF IMMUNITY IN ADOPTIVELY IMMUNIZED VIRUS CARRIERS. , 1964, Acta pathologica et microbiologica Scandinavica.